Terapia skojarzona nadciśnienia tętniczego z zastosowaniem lisinoprilu u pacjentów ze współistniejącą cukrzycą – punkt widzenia diabetologa Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2013
Słowa kluczowe:
nadciśnienie tętnicze, cukrzyca, terapia skojarzona, lisinopril
##plugins.themes.bootstrap3.article.main##
Abstrakt
Nadciśnienie tętnicze oraz cukrzyca to schorzenia często współistniejące, w istotny sposób zwiększające ryzyko zgonu z przyczyn sercowo-naczyniowych. Skuteczne leczenie cukrzycy obejmuje nie tylko wyrównanie gospodarki węglowodanowej, ale także wyrównanie gospodarki lipidowej oraz skuteczną redukcję wysokości ciśnienia tętniczego. W terapii nadciśnienia u pacjentów ze współistniejącą cukrzycą zaleca się przede wszystkim stosowanie leków blokujących układ renina–angiotensyna–aldosteron. W wielu przypadkach korzystne jest również stosowanie od początku leczenia skojarzonego. W artykule autorzy omawiają rolę terapii skojarzonej opartej na stosowaniu lisinoprilu w połączeniu z hydrochlorotiazydem lub amlodypiną.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Duda-Król, W. B., & Wełnicki , M. (2013). Terapia skojarzona nadciśnienia tętniczego z zastosowaniem lisinoprilu u pacjentów ze współistniejącą cukrzycą – punkt widzenia diabetologa . Medycyna Faktów , 6(4(21), 21-25. Pobrano z https://www.journalsmededu.pl/index.php/jebm/article/view/2391
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2013. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabet. Klin. 2013; 2(supl. A): A1-A66.
2. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013; 34: 2159-2219.
3. International Diabetes Federation. Diabetes Atlas, 6th ed. Belgium, Brussels 2013 [online: http://www.idf.org/diabetesatlas].
4. Sieradzki J., Grzeszczak W., Karnafel W. et al.: Badanie PolDiab. Część I. Analiza leczenia cukrzycy w Polsce. Diabetologia Praktyczna 2006; 7(1): 8-15.
5. Sowers J.R., Epstein M., Frohlich E.D.: Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37: 1053-1059.
6. Wong N.D., Lopez V.A., L’Italien G. et al.: Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003- 2004. Arch. Intern. Med. 2007; 167: 2431-2436.
7. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br. Med. J. 1998; 317: 703-713.
8. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Antihypertensive and Lipid-Lowering Treatment to Inhibitor or Calcium Channel Blocker vs Diuretic: The Randomized to Angiotensin-Converting Enzyme Major Outcomes in High-Risk Hypertensive Patients Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981-2997.
9. Wright J.T. Jr, Dunn J.K., Cutler J.A. et al.; ALLHAT Collaborative Research Group: Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005; 293(13): 1595-1608.
10. Barzilay J.I., Davis B.R., Cutler J.A. et al.: Fasting Glucose Levels and Incident Diabetes Mellitus in Older Nondiabetic Adults Randomized to Receive 3 Different Classes of Antihypertensive Treatment: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med. 2006; 166(20): 2191-2201.
11. Barylski M., Bielecka-Dąbrowa A., Ciebiada M.: Lizinopril w terapii chorób układu sercowo-naczyniowego-skuteczność potwierdzona w badaniach. Geriatria 2011; 5: 55-64.
12. Mogensen C.E., Neldam S., Tikkanen I. et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444.
13. The EUCLID Study Group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997; 2: 1787-1792.
14. Chaturvedi N., Sjolie A.K., Stephenson J.M. et al.: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes Lancet 1998; 351: 28-31.
15. Farsang C.; HAMLET Trial Investigation: Advantages of lisinopril amlodypine fixed combination therapy in hypertension. A comparative study of the efficacy and tolerability of amlodipine 5 mg and lisinopril 10 mg administered separately and in combination in hypertension. Hypertonia es Nephrologia 2004; 8: 72-78.
16. Poldermans D., Glazes R., Kargiannis S. et al.: Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin. Ther. 2007; 29(2): 279-289.
17. Gerc V., Begović B., Vehabović M. et al.: Effects of fixed combination of lisinopril plus hydrochlorothiazide on regression of left ventricular hypertrophy in patients with essential hypertension: an opened, multi-centre, prospective clinical trial. Bosn. J. Basic. Med. Sci. 2008; 8(3): 214-9.
18. Corrao G., Parodi A., Zambon A. et al.: Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J. Hypertens. 2010; 28: 1584-1590.
19. Gupta A.K., Arshad S., Poulter N.R.: Compliance, safety and effectiveness of fixe dose combinations of antihypertensive agents; a meta-analysis. Hypertension 2010; 55: 399-407.
20. Claxton A.J., Kramer J., Pierce C.: A systematic review of the association between dose regiment and medication compliance. Clin. Ther. 2001; 23: 1296-1310.
21. Wald D.S., Law M., Morris J.K. et al.: Combination therapy versus monotherapy in reducing blood pressure: metaanalysis on 11.000 participants from 42 trials. Am. J. Med. 2009; 122: 290-300.
2. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013; 34: 2159-2219.
3. International Diabetes Federation. Diabetes Atlas, 6th ed. Belgium, Brussels 2013 [online: http://www.idf.org/diabetesatlas].
4. Sieradzki J., Grzeszczak W., Karnafel W. et al.: Badanie PolDiab. Część I. Analiza leczenia cukrzycy w Polsce. Diabetologia Praktyczna 2006; 7(1): 8-15.
5. Sowers J.R., Epstein M., Frohlich E.D.: Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37: 1053-1059.
6. Wong N.D., Lopez V.A., L’Italien G. et al.: Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003- 2004. Arch. Intern. Med. 2007; 167: 2431-2436.
7. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br. Med. J. 1998; 317: 703-713.
8. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Antihypertensive and Lipid-Lowering Treatment to Inhibitor or Calcium Channel Blocker vs Diuretic: The Randomized to Angiotensin-Converting Enzyme Major Outcomes in High-Risk Hypertensive Patients Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981-2997.
9. Wright J.T. Jr, Dunn J.K., Cutler J.A. et al.; ALLHAT Collaborative Research Group: Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005; 293(13): 1595-1608.
10. Barzilay J.I., Davis B.R., Cutler J.A. et al.: Fasting Glucose Levels and Incident Diabetes Mellitus in Older Nondiabetic Adults Randomized to Receive 3 Different Classes of Antihypertensive Treatment: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med. 2006; 166(20): 2191-2201.
11. Barylski M., Bielecka-Dąbrowa A., Ciebiada M.: Lizinopril w terapii chorób układu sercowo-naczyniowego-skuteczność potwierdzona w badaniach. Geriatria 2011; 5: 55-64.
12. Mogensen C.E., Neldam S., Tikkanen I. et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444.
13. The EUCLID Study Group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997; 2: 1787-1792.
14. Chaturvedi N., Sjolie A.K., Stephenson J.M. et al.: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes Lancet 1998; 351: 28-31.
15. Farsang C.; HAMLET Trial Investigation: Advantages of lisinopril amlodypine fixed combination therapy in hypertension. A comparative study of the efficacy and tolerability of amlodipine 5 mg and lisinopril 10 mg administered separately and in combination in hypertension. Hypertonia es Nephrologia 2004; 8: 72-78.
16. Poldermans D., Glazes R., Kargiannis S. et al.: Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin. Ther. 2007; 29(2): 279-289.
17. Gerc V., Begović B., Vehabović M. et al.: Effects of fixed combination of lisinopril plus hydrochlorothiazide on regression of left ventricular hypertrophy in patients with essential hypertension: an opened, multi-centre, prospective clinical trial. Bosn. J. Basic. Med. Sci. 2008; 8(3): 214-9.
18. Corrao G., Parodi A., Zambon A. et al.: Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J. Hypertens. 2010; 28: 1584-1590.
19. Gupta A.K., Arshad S., Poulter N.R.: Compliance, safety and effectiveness of fixe dose combinations of antihypertensive agents; a meta-analysis. Hypertension 2010; 55: 399-407.
20. Claxton A.J., Kramer J., Pierce C.: A systematic review of the association between dose regiment and medication compliance. Clin. Ther. 2001; 23: 1296-1310.
21. Wald D.S., Law M., Morris J.K. et al.: Combination therapy versus monotherapy in reducing blood pressure: metaanalysis on 11.000 participants from 42 trials. Am. J. Med. 2009; 122: 290-300.